☆ 4.7 Meeting Abstract

ENHANCING THE ANTI-TUMOR IMMUNITY AND THERAPEUTIC POTENTIAL OF ICT01, A BUTYROPHILIN3A-TARGETED, γ9δ2 T CELL-ACTIVATING MONOCLONAL ANTIBODY, WITH LOW DOSE IL-2 IN PATIENTS WITH ADVANCED SOLID TUMORS: THE EVICTION-2 TRIAL

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Get Full Text
Add to Collection

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 10, Issue -, Pages A753-A753

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-SITC2022.0720

Keywords

-

Categories

Oncology Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.